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Introduction
The introduction of efficacious agents like thalidomide,
lenalidomide, and bortezomib in the treatment of multiple
myeloma (MM) has placed greater importance on health-relat-
ed quality of life (HRQoL) as an outcome measure1-7 and a fac-
tor that influences treatment decisions.8-11 In the randomized
phase III MM-015 trial of patients with newly diagnosed MM
(NDMM) aged 65 years or over, median progression-free sur-
vival (PFS) was significantly longer with the combination of
melphalan, prednisone, and lenalidomide, followed by
lenalidomide maintenance therapy (MPR-R; 31 months) than
with MPR or MP without maintenance therapy (14 and 13
months, respectively; P<0.0001 for both).12 A pre-defined sec-
ondary end point of the MM-015 trial was HRQoL. The pri-
mary goal of this analysis was to compare HRQoL outcomes
in the MPR-R and MP groups. Because the PFS benefit with
MPR-R was observed primarily in the subset of patients aged
65-75 years,12,13 HRQoL outcomes in this subset were also
assessed.
Design and Methods
MM-015 is a prospective, multicenter, phase III, randomized, dou-
ble-blind, placebo-controlled, 3-arm parallel group study. Full study
details are provided elsewhere.12 Briefly, patients were randomized
(1:1:1) to one of 3 treatment arms, which involved nine 28-day cycles
of; i) MPR followed by maintenance therapy with lenalidomide (MPR-
R); ii) MPR followed by maintenance therapy with placebo, MPR); iii)
MP plus placebo followed by maintenance therapy with placebo (MP)
(Online Supplementary Figure S1). Patients receive maintenance therapy
until: i) progressive disease (PD); ii) discontinuation for reasons other
than PD (DC); iii) all patients are followed for at least five years from
randomization or until death. The study was conducted in compliance
with the Independent Review Board/Independent Ethics Committee
procedures, the Declaration of Helsinki, the International Conference
on Harmonisation Guideline for Good Clinical Practice, and local reg-
ulations governing the conduct of clinical studies. Written informed
consent was obtained from all patients before enrollment.
Two European Organization for Research and Treatment of Cancer
(EORTC) HRQoL questionnaires were used: the generic 30-item
EORTC QLQ-C30,14 and the 20-item MM-specific module EORTC
QLQ-MY20.15 Each questionnaire takes approximately 10-15 min to
complete.16 The QLQ-C30 includes 5 functional domains (Physical
Functioning, Emotional Functioning, Cognitive Functioning, Social
Functioning, and Role Functioning), where a higher score indicates
better function. For the 9 symptom domains (Fatigue,
Nausea/Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss,
Constipation, Diarrhea, and Financial Difficulties), lower scores indi-
cate fewer symptoms. The QLQ-C30 also contains an item on overall
Global Health Status/QoL (subsequently referred to as Global QoL),
where a higher score indicates better quality of life. The QLQ-MY20
includes 2 functional domains (Future Perspective and Body Image)
and 2 symptom domains (Disease Symptoms and Side Effects of
Treatment). Higher scores indicate better function and more symp-
toms, respectively. At the time this study was initiated, the 24-item
©2013 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2012.074534
The online version of this article has a Supplementary Appendix. Manuscript received on July 22, 2012. Manuscript accepted on November 22, 2012.
Correspondence: mdimop@med.uoa.gr 
The MM-015 trial assessed the effect of lenalidomide-based therapy on health-related quality of life. Patients (n=459)
with newly diagnosed multiple myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of
lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and
prednisone, or melphalan and prednisone, with no maintenance therapy. Patients completed health-related quality
of life questionnaires at baseline, after every third treatment cycle, and at treatment end. Health-related quality of life
improved in all treatment groups during induction therapy. Patients receiving lenalidomide maintenance had the
most pronounced improvements, Global Health Status/Quality of Life (P<0.05), Physical Functioning (P<0.01), and
Side Effects of Treatment (P<0.05) out of 6 pre-selected health-related quality of life domains. More patients receiving
lenalidomide maintenance achieved minimal important differences (P<0.05 for Physical Functioning). Therefore,
lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of
life in patients with newly diagnosed multiple myeloma. (Clinicaltrials.gov identifier NCT00405756).
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QLQ-MY24 was in development, and 4 questions regarding social
support were removed during validation, resulting in the validated
QLQ-MY20.15 For consistency, the QLQ-MY24 form was admin-
istered throughout this study, but the 4 questions removed during
validation were omitted from the analysis. 
Questionnaires were completed at baseline; after every third
treatment cycle (i.e. before starting cycles 4, 7, 10, 13, 16, etc.); and
at the time of treatment discontinuation due to PD or DC. Follow-
up included HRQoL assessment every 6 months (168 days) during
the open-label extension phase. Six HRQoL domains were selected
a priori for analysis based on their perceived clinical relevance:
Global QoL, Physical Functioning, Fatigue, and Pain from QLQ-
C30, and Disease Symptoms, and Side Effects of Treatment from
QLQ-MY20. Domain scores were calculated if responses were
given to at least 50% of items in that particular domain.17
Compliance rates with HRQoL reporting were calculated for each
time point across treatment groups. Mixed models were used to
estimate the treatment effect on HRQoL over time, adjusted and
unadjusted for baseline HRQoL scores (Online Supplementary
Methods). 
The minimal important difference (MID) was calculated to help
identify clinically meaningful changes in HRQoL scores from base-
line, irrespective of whether they were of statistical signifi-
cance.18,19 Domain-specific MIDs of the 6 pre-selected domains
were identified by calculating the standard error of measurement
(SEM).20,21 Positive MIDs denote improvements for the HRQoL
domains Global QoL and Physical Functioning; negative values
denote improvements in Pain, Fatigue, Disease Symptoms, and
Side Effects of Treatment. 
Cumulative distribution frequency (CDF) graphs were also plot-
ted for each of the 6 pre-selected HRQoL domains at cycles 10 and
16 (Online Supplementary Methods).
Statistical methodology is described in the Online Supplementary
Methods. 
Results and Discussion
From February 2007 to September 2008, 459 patients
were enrolled at 82 treatment centers and randomized to
MPR-R (n=152), MPR (n=153), or MP (n=154). Patient
demographics and disease-related characteristics are
described in the Online Supplemental Results. Compliance
rates were generally high (>76% across assessment time
points considered and >65% at PD/DC) and consistent
across treatment groups (Online Supplemental Results).
Health-related quality of life scores during 
induction therapy
At baseline, patients randomized to MPR-R had worse
HRQoL scores than those assigned to MPR or MP (Table 1),
but the difference was statistically significant only for
Physical Functioning (P=0.014). Longitudinal HRQoL data
for all patients are shown in Figure 1. During induction,
mean Global QoL scores increased (i.e. improved) by 12.2
in MPR-R (P<0.001) and 6.2 in MP (P<0.05), and mean
Physical Functioning scores increased (i.e. improved) by 9.0
in MPR-R (P<0.001) and 5.1 in MP (P<0.01). Mean Fatigue
scores decreased (i.e. improved) by 7.5 in MPR-R (P<0.01)
and 6.9 in MP (P<0.01), as did mean Pain scores (-17.2 for
MPR-R and -9.8 for MP; both P<0.001) and Disease
Symptoms scores (-7.9 for MPR-R, P<0.001; and 
-5.4 for MP, P<0.01) (Table 1). Scores for Side Effects of
Treatment showed minimal changes from baseline in both
MPR-R (-1.6) and MP patients (+0.3), and both changes
were not significant. The improvement in HRQoL from
baseline in MPR-R patients aged 65-75 years was slightly
greater than that for all MPR-R patients (Online Supplementary
Results and Figure S2). Comparable changes in HRQoL
scores could not be replicated in the smaller subgroup of
patients aged over 75 years.
Health-related quality of life scores during 
maintenance therapy
Improvements in HRQoL observed during MPR induc-
tion were maintained in patients receiving lenalidomide
maintenance therapy (Table 1). In the MPR-R group, statis-
tically significant improvements were seen at cycle 16 com-
pared with baseline for all domains, except Side Effects of
Treatment. Statistically significant improvements were not
consistently observed for MPR and MP patients. 
Analyses of both induction and maintenance therapy
Results of the mixed-model analyses indicated a signifi-
cant difference in changes in Physical Functioning scores
across treatment groups: scores improved significantly
(P<0.05) from baseline in MPR-R and MPR patients but
worsened in MP patients (interaction term P=0.004) (Online
Supplementary Figure S3). Scores in the other domains showed
the same pattern: scores improved (the slope was positive
and significant for Global QoL [P<0.05] and negative for the
symptom domains Side Effects of Treatment [P<0.05],
Fatigue and Pain) in the MPR-R arm and worsened (the
slope was negative for Global QoL and positive for Fatigue,
Pain and Disease Symptoms) in the MP arm (Online
Supplementary Figure S3). Where slopes were equal in sign
between MPR-R and MP (Disease Symptoms and Side
Effects of Treatment) HRQoL changes were more favorable
for MPR-R patients. The results were similar after adjust-
ment for baseline HRQoL scores, patient and disease char-
acteristics, with Physical Functioning scores significantly
improving (positive slope) in both MPR (P<0.05) and MPR-
R (P<0.01) patients, and both patient groups improving sig-
nificantly more than MP patients (both P<0.01), whose
scores worsened. While there was no statistically significant
group difference in Global QoL scores (P=0.11 for MPR-R
vs. MP), MPR-R patients reported significant improvement
(P<0.05) with a positive slope coefficient. MPR-R patients
also reported a significant improvement (negative slope
coefficient) in Side Effects of Treatment (P<0.05) (Online
Supplementary Figure S4). Across the other HRQoL domains,
HRQoL with MPR-R improved in seven of the thirteen
domains (QLQ-C30 Role Functioning, Emotional
Functioning, Social Functioning, Nausea/Vomiting,
Appetite Loss, Constipation, and QLQ-MY20 Future
Perspectives). QLQ-C30 Cognitive Functioning, Dypsnea
and Insomnia worsened for both MPR-R and MP, but less
so in the MPR-R group. In the 3 remaining domains (QLQ-
C30 Diarrhea, Financial Difficulties, and QLQ-MY20 Body
Image), HRQoL worsened for MPR-R and improved for MP,
but differences between MPR-R and MP were only statisti-
cally significant for Diarrhea (P<0.05). Similarly, other than
Diarrhea (P<0.05), none of the slopes for the six HRQoL
scores showing a worsening trend for MPR-R were statisti-
cally significantly different from zero, this is equivalent to a
stabilization in HRQoL. 
Minimal important differences
Observed MIDs for each HRQoL domain and the assess-
ment time points at which patients in each arm on average
MPR-R HRQoL impact
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achieved the MID are presented in Table 2. MID values
ranged from an absolute value of 6 (Side Effects of
Treatment) to an absolute value of 12 (Pain). Over time,
clinically meaningful improvements in HRQoL, as deter-
mined by the MID, were more frequently observed in
patients receiving MPR-R than those receiving MPR or MP.
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Table 1. HRQoL mean (SD) domain scores by study arm during the induction and maintenance phases (including within-group changes from baseline
and cycle 10) by (A) EORTC QLQ-C30 and (B) EORTC QLQ-MY20 questionnaires.
A
Induction Maintenance Cycle 16 vs. BL
Study arm BL Cycle 4 Cycle 7 Cycle 10 Cycle 10 vs. BL Cycle 13 Cycle 16 Cycle 16 vs. 10
QLQ-C30 Global QoL
MPR-R  49.6(23.5) 54.2(20.2) 61.3(19.3) 63.7(18.0) +12.2(25.4)*** 61.6(20.1) 62.2(17.1) -4.1(14.9)* +11.3(25.1)** 
(N=152) n=137 n=122 n=103 n=90 n=83 n=74 n=64 n=61 n=60
MPR 53.2(23.5) 58.4(20.5) 58.9(22.6) 61.4(22.7) +8.8(24.7)*** 61.8(21.3) 63.3(18.4) +0.4(16.8) +7.0(26.5)
(N=153) n=142 n=128 n=117 n=91 n=86 n=76 n=54 n=46 n=49
MP 52.8(22.8) 58.5(20.1) 58.0(19.4) 61.5(18.3) +6.2(24.6)* 60.5(19.0) 61.9(18.9) +1.0(17.0) +8.1(25.1)
(N=154) n=147 n=132 n=116 n=100 n=96 n=84 n=65 n=60 n=62
QLQ-C30 Physical Functioning
MPR-R  57.5(25.3) 61.6(23.6) 66.3(22.2) 68.6(20.7) +9.0(22.9)*** 71.3(20.0) 72.6(20.3) +0.3(11.7) +10.2(25.2)**
(N=152) n=140 n=126 n=106 n=91 n=87 n=77 n=65 n=62 n=63
MPR 64.0(24.3) 67.4(22.3) 71.0(20.4) 71.0(22.8) +8.5(25.6)*** 72.2(22.2) 73.2(17.3) +1.9(15.2) +7.6(22.7)*
(N=153) n=146 n=132 n=118 n=99 n=95 n=78 n=56 n=50 n=53
MP 65.5(23.8) 70.4(21.9) 69.1(23.0) 72.2(19.2) +5.1(20.4)** 69.8(21.1) 67.6(20.2) −2.0(13.3) +1.1(19.3)
(N=154) n=148 n=136 n=117 n=99 n=96 n=84 n=65 n=60 n=63
QLQ-C30 Fatigue
MPR-R  49.3(25.6) 43.6(24.2) 39.7(23.2) 39.4(23.3) −7.5(27.3)** 36.8(21.8) 35.2(22.4) +0.5(15.6) −10.1(27.0)*
(N=152) n=140 n=126 n=105 n=91 n=87 n=76 n=65 n=61 n=63
MPR 44.2(27.1) 38.8(24.2) 34.2(23.4) 36.3(26.1) −7.6(29.8)*** 33.5(22.7) 31.3(20.4) −3.0(15.9) −9.7(28.8)
(N=153) n=146 n=132 n=118 n=99 n=95 n=78 n=55 n=50 n=53
MP 42.6(27.4) 37.2(22.7) 35.9(20.7) 33.3(22.0) −6.9(28.3)** 33.0(20.5) 37.3(21.8) +3.3(18.2) −4.1(26.3)*
(N=154) n=147 n=136 n=116 n=99 n=95 n=84 n=65 n=59 n=62
QLQ-C30 Pain
MPR-R  48.8(34.8) 31.9(27.7) 30.5(27.0) 31.7(27.0) −17.2(34.8)*** 31.4(28.3) 28.0(24.5) −1.6(18.5) −21.4(33.0)***
(N=152) n=140 n=126 n=105 n=92 n=88 n=76 n=65 n=62 n=63
MPR 44.9(30.2) 31.4(27.7) 28.4(26.7) 28.1(29.3) −15.6(35.3)*** 31.0(24.7) 33.6(22.8) +4.6(24.3) −11.0(33.0)*
(N=153) n=146 n=132 n=118 n=99 n=95 n=78 n=55 n=50 n=53
MP 43.5(33.0) 31.2(28.8) 31.1(28.4) 31.2(27.1) −9.8(31.7)*** 30.6(24.9) 31.3(25.4) +0.6(24.0) −12.2(30.0)** 
(N=154) n=148 n=135 n=118 n=100 n=97 n=84 n=65 n=60 n=63
B
Induction Maintenance Cycle 16 vs. BL
Study arm BL Cycle 4 Cycle 7 Cycle 10 Cycle 10 vs. BL Cycle 13 Cycle 16 Cycle 16 vs. 10
QLQ-MY20 Disease Symptoms
MPR-R  34.0(23.6) 23.3(18.4) 22.7(17.8) 25.6(18.9) −7.9(23.0)*** 24.8(20.5) 23.7(20.4) −0.9(14.7) −11.4(23.2)**
(N=152) n=138 n=122 n=102 n=91 n=85 n=75 n=65 n=61 n=61
MPR 32.1(21.5) 24.3(19.3) 22.8(19.2) 24.4(19.7) −7.1(23.9)*** 24.9(17.9) 26.7(18.5) +1.4(16.1) −5.9(25.8)
(N=153) n=142 n=128 n=118 n=97 n=91 n=78 n=55 n=49 n=51
MP 32.3(22.4) 26.9(21.4) 26.1(20.2) 26.2(19.4) −5.4(18.8)** 26.9(20.2) 29.4(19.8) +2.2(16.0) −3.4(20.7)
(N=154) n=148 n=133 n=127 n=98 n=95 n=83 n=64 n=57 n=62
QLQ-MY20 Side Effects of Treatment
MPR-R  20.6(15.0) 20.9(13.2) 19.8(13.7) 18.7(15.2) −1.6(14.5) 14.9(13.7) 17.8(12.9) +0.9(8.3) −2.6(14.5)
(N=152) n=138 n=122 n=101 n=91 n=85 n=75 n=65 n=61 n=61
MPR 19.0(15.8) 19.1(15.1) 17.6(16.5) 17.4(16.8) 0.0(16.0) 16.4(13.3) 15.4(14.5) −2.9(11.7)   −2.9(14.2)
(N=153) n=141 n=128 n=118 n=96 n=89 n=78 n=55 n=48 n=50
MP 17.1(14.4) 17.8(14.1) 17.9(12.3) 16.0(14.3) +0.3(12.6) 15.7(12.8) 16.0(12.5) +0.6(11.8) −0.9(12.2)
(N=154) n=147 n=132 n=116 n=98 n=94 n=83 n=64 n=57 n=61
The P value is calculated based on a paired t-test (within-group mean change): *P<0.05; **P<0.01; ***P<0.001. HRQoL observations at PD/DC, if occurring earlier than cycle 16 were carried
forward to the next measurement time point. BL: baseline; MP: melphalan and prednisone; MPR: melphalan, prednisone, and lenalidomide; MPR-R: melphalan, prednisone, and lenalidomide
followed by lenalidomide maintenance therapy. 
Achievement of the MID was observed as early as cycle 4
for Pain; at cycle 16, the MID was reached in 5 of the 6
domains in patients receiving MPR-R, but in only 2 of the 6
domains in patients receiving MP. Changes in HRQoL
scores from baseline to cycles 10 and 16, as depicted in CDF
graphs, generally favored MPR-R over MP, both overall and
in the subset of patients aged 65-75 years (Online
Supplementary Figures S5 and S6) as also indicated by the
percentages of patients achieving the MID in each treat-
ment arm (Online Supplementary Figure S7). 
Discussion
In this analysis, statistically significant improvements in
HRQoL from baseline were observed in all treatment
arms (MPR-R, MPR, and MP) for all HRQoL domains
assessed, except QLQ-MY20 Side Effects of Treatment.
Improvements in HRQoL score from baseline were gen-
erally greater in patients who received lenalidomide, and
the difference was statistically significant for QLQ-C30
Physical Functioning (MPR-R vs.MP). Clinically meaning-
ful improvements in HRQoL from baseline were more
frequently observed in patients who received MPR-R
than those who received MP. The results therefore pro-
vide evidence of a favorable effect of MPR-R over MP in
terms of Physical Functioning, and a clear trend in
improvements in all other HRQoL domains tested,
including Global QoL, Fatigue, Pain, and Disease
Symptoms. The statistically non-significant change in
Side Effects of Treatment scores from baseline in the
MPR-R group and its comparability with scores in the MP
group highlights the favorable tolerability profile of the
MPR-R regimen, both during induction and maintenance.
MPR-R HRQoL impact
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Table 2. Observed MIDs from baseline.
Baseline scores Assessment time points (cycle) with 
patients on average achieving MID3
HRQoL domain Mean SD Internal SEM MID2 MPR-R MPR MP
score (range 0–100) consistency1
Global QoL 51.9 23.3 0.917 6.71 +7 7, 10, 13, 16 7, 10, 13 16
Physical Functioning 62.4 24.4 0.862 9.06 +9 10, 13, 16 13 None observed
Fatigue 45.3 26.8 0.867 9.77 −10 16 13 None observed
Pain 45.7 32.7 0.874 11.61 −12 4, 7, 10, 13, 16 4, 7, 10, 13 4, 13, 16
Disease Symptoms 32.8 22.5 0.791 10.29 −10 16 None observed None observed
Side Effects of Treatment 18.8 15.1 0.845 5.94 −6 None observed None observed None observed
1Cronbach’s alpha. 2Thresholds for clinically meaningful score changes from baseline are based on domain-specific distribution based methods (1 SEM). Positive values denote
improvements for Global Quality of Life and Physical Functioning. Negative values denote improvements for Pain, Fatigue, Disease Symptoms and Side Effects of Treatment. 3Data
from patients who discontinued from the study prior to cycle 16 were carried forward to the next planned measurement time point in analysis. HRQoL: health-related quality of life;
MID: minimal important difference; MP: melphalan and prednisone; MPR: melphalan, prednisone, and lenalidomide; MPR-R: melphalan, prednisone, and lenalidomide, followed by
lenalidomide maintenance therapy; SEM: standard error of measurement; SD: standard deviation. 
Figure 1. EORTC QLQ-C30 and QLQ-MY20 mean domain scoresa with
standard error bars by study armb during both induction and mainte-
nance phases. aAn increase in Global QoL and Physical Functioning
scores represents an improvement in HRQoL, while the reverse
applies to the other domain scores. Data during the induction phase
were previously displayed as pooled score averages from the MPR-R
and MPR arms, 22but are now presented for each arm (see Table 1).
bConnecting lines between separate time points are included for visu-
alization purposes: the numbers of patients at each assessment
change over time. MP: melphalan and prednisone; MPR: melphalan,
prednisone, and lenalidomide; MPR-R: melphalan, prednisone, and
lenalidomide, followed by lenalidomide maintenance therapy.
Cycle CycleCycleCycleCycleCycle
1 4 7 10 13 16
Cycle CycleCycleCycleCycleCycle
1 4 7 10 13 16
Assessment time point 
(beginning of cycle)
Cycle CycleCycleCycleCycleCycle
1 4 7 10 13 16
Assessment time point 
(beginning of cycle)
Cycle CycleCycleCycleCycleCycle
1 4 7 10 13 16
Assessment time point 
(beginning of cycle)














































































































































1 4 7 10 13 16
Assessment time point 
(beginning of cycle)
Cycle CycleCycleCycleCycleCycle
1 4 7 10 13 16













































































































The results observed in patients aged 65-75 years were
consistent with findings from the overall study popula-
tion. It is possible that observed improvements in HRQoL
could be a cumulative effect of the withdrawal of more
severely ill patients with poorer HRQoL. However, use of
the mixed-model repeated measures analysis across time
points helped to ensure that any observed changes were
not attributable primarily to the changing nature of the
sample over time. The comparable findings among the
MPR-R, MPR, and MP groups in terms of patient and dis-
ease characteristics as well as HRQoL compliance rates
further suggest balanced HRQoL findings across treat-
ment arms. The MID estimates for QLQ-C30 ranged
from 6 to 12 points, consistent with previously reported
MIDs23 (Online Supplementary Information).
These findings differ from those of the VISTA trial, which
evaluated the addition of bortezomib to MP (VMP) in trans-
plant-ineligible patients with NDMM.24 Since in the VISTA
trial, HRQoL scores worsened during the first 4 cycles of
VMP therapy compared with baseline and with MP, further
studies are needed directly to compare the HRQoL impact
of novel anti-myeloma treatment regimens.
In summary, NDMM patients treated with MPR-R report
steady improvements in HRQoL during therapy, including
a significantly greater improvement in Physical Functioning
compared with patients treated with MP. Results were
comparable and slightly more favorable in patients aged 65-
75 years. These findings, taken together with the primary
results of the MM-015 trial, demonstrate that MPR-R is a
safe and effective treatment option for patients with
NDMM that may lead to improved HRQoL.
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